Drug Profile
Research programme: anticancer therapeutics - Florida Atlantic University
Alternative Names: SIM2 inhibitors - Affitech/FAULatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Florida Atlantic University
- Developer Florida Atlantic University; Torrey Pines Institute for Molecular Studies
- Class Antisense elements
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 08 May 2007 Florida Atlantic University and Torrey Pines Institute for Molecular Studies are collaborating in the development of SIM2 inhibitors
- 19 Jun 2003 A preclinical study has been added to the Cancer pharmacodynamics section